2.61
-0.16(-5.78%)
Currency In USD
| Previous Close | 2.77 |
| Open | 2.75 |
| Day High | 2.75 |
| Day Low | 2.56 |
| 52-Week High | 7.03 |
| 52-Week Low | 1.64 |
| Volume | 10.64M |
| Average Volume | 14.54M |
| Market Cap | 865.71M |
| PE | -2.19 |
| EPS | -1.19 |
| Moving Average 50 Days | 2.37 |
| Moving Average 200 Days | 2.42 |
| Change | -0.16 |
If you invested $1000 in Iovance Biotherapeutics, Inc. (IOVA) 10 years ago, it would be worth $397.26 as of January 08, 2026 at a share price of $2.61. Whereas If you bought $1000 worth of Iovance Biotherapeutics, Inc. (IOVA) shares 5 years ago, it would be worth $51.66 as of January 08, 2026 at a share price of $2.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
GlobeNewswire Inc.
Nov 03, 2025 12:00 PM GMT
26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Iovance Bio
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
GlobeNewswire Inc.
Oct 23, 2025 8:05 PM GMT
SAN CARLOS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patient
Iovance Biotherapeutics to Present at Upcoming Conferences
GlobeNewswire Inc.
Aug 29, 2025 12:30 PM GMT
SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patient